Table 1.

Clinical and pathologic characteristics of gender-mismatched and gender-matched (control) BMT subjects

Patient no.	Gender [D]	Gender [R]	Age, years	Underlying disease	Conditioning regimen	Graft duration, days	Coronary pathology
Gender-mismatched bone marrow transplant subjects
1	Male	Female	42	Chronic lymphocytic leukemia	Cyclophosphamide TBI	964	Grade III fibrocellular plaque
2	Male	Female	46	Chronic granulocytic leukemia	Cyclophosphamide busulphan	501	Grade II fibrocellular plaque
3	Male	Female	33	Chronic granulocytic leukemia	Cyclophosphamide TBI	41	Grade III fibrocellular plaque
4	Male	Female	30	Myelodysplastic syndrome	Cyclophosphamide TBI	90	Diffuse intimal thickening
5	Female	Male	39	Myeloma	Cyclophosphamide busulphan	1235	Grade III fibrocellular plaque
6	Female	Male	29	Myelodysplastic syndrome	Cyclophosphamide TBI	78	Grade III fibrocellular plaque
7	Female	Male	45	Acute myelogenous leukemia	Cyclophosphamide TBI	131	Grade III fibrocalcific plaque
8	Female	Male	58	Myelofibrosis	Cyclophosphamide busulphan	91	Diffuse intimal thickening
Gender-matched bone marrow transplant subjects
9	Male	Male	55	Myelodysplastic syndrome	Cyclophosphamide TBI	655	Grade II fibrocellular plaque
10	Male	Male	46	Acute lymphocytic leukemia	Cyclophosphamide TBI	527	Grade III fibrocellular plaque
11	Male	Male	45	Myelodysplastic syndrome	Cyclophosphamide TBI	153	Diffuse intimal thickening
12	Female	Female	46	Chronic granulocytic leukemia	Cyclophosphamide busulphan	108	Diffuse intimal thickening
13	Female	Female	52	Chronic granulocytic leukemia	Cyclophosphamide TBI	901	Grade II fibrolipid plaque

[D] and [R] indicate donor and recipient, respectively. TBI, total body irradiation.